DOCSLIB.ORG

DOH Drug Price Reference 2013

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DOH Drug Price Reference 2013 ACKNOWLEDGEMENTS The Second Edition of the Drug Price Reference Index (DPRI) was made possible with the hard work, dedication and team effort of the National Center for Pharmaceutical Access and Management’s DPRI Team headed by Mr. Manuel Alexander Haasis, Project Manager/Consultant and Ms. Marinette J. Ladioray, Senior Health Program Officer, together with the team members namely: Mr. Achilles Aragona, Information System Researcher II, Mr. Julius Jocson, Health Program Officer I, Mr. John Irving Telingban, Supply Officer I and Mr. Jeffrey Castro, Health Program Researcher and all NCPAM staff for their support. We also acknowledge the guidance of the System Support Division Head, Ms. Vanessa Saulog-Obera and lastly to the unwavering support and supervision of Dr. Anna Melissa S. Guerrero, OIC- Program Manager, NCPAM, Dir. Lilibeth C. David, OIC- Health Policy Finance and Research Development Cluster, and Dr. Madeleine De Rosas-Valera, former Undersecretary of Health. 13 October 2014 Manila, Philippines 1 | P a g e Overview The high and extremely variable prices of medicines in the Philippines impact on access to effective, efficient and equitable health care. In 2009, a study conducted by Health Action International revealed that there was extreme variability in the procurement prices of essential medicines in the national and local public health facilities in the country. On average, originator brands and generic equivalents were procured almost 16 times and 3 times higher, respectively, compared to prices available on the international market. 1 DOH-Central Office Bids and Awards Committee (DOH-COBAC) and DOH hospitals were shown to have more efficient procurement prices compared to provincial and municipal health facilities, thus leading to variability in access to essential medicines across the Philippines. Republic Act (RA) 9502 or the Universally Accessible Cheaper and Quality Medicines Act of 2008 gave the DOH instruments to monitor and regulate the prices of drugs and medicines to protect consumers and the public procuring entities from excessive mark-ups applied to prices of medicines resulting from information asymmetry and the lack of effective market competition. To address these issues, the National Center for Pharmaceutical Access and Management (NCPAM) has established a Drug Price Reference Index (DPRI) for all essential medicines to guide all national and local government health facilities in the efficient sourcing of pharmaceutical products in the public sector. What is the Drug Price Reference Index (DPRI)? The DPRI lists the ceiling prices of essential medicines for government bidding and procurement set by the DOH for all DOH Retained Hospitals and Regional Health Offices (RHOs). Winning bid prices of essential medicines within the DPRI ceiling reflect efficient and effective procurement that facilitates consumer access to medicines and protection from excessive mark-ups of prices. The DPRI only reflects the acquisition costs including landed cost, packaging, drug content, quality assurance, manufacturing overheads and Food and Drug Administration (FDA) fees. The DPRI excludes other costs such as pharmacy services, preparation and storage fees and applicable taxes to medicines (i.e. VAT), and other reasonable pharmacy mark-ups, which are now being evaluated by the DOH. The DPRI aims to improve the efficiency and good governance in the pricing and procurement of medicines in the public sector through establishing a transparent and publicly available reference price for affordable and quality medicines. It also aims to guide the Philippine Health Insurance Corporation (PHIC) in setting reimbursement caps for medicines both for inpatient and outpatient services. Who should use the DPRI? All government entities should be guided by the DPRI when procuring medicines. It shall be applied to all forms of procurement such as public bidding, direct contracting, shopping, negotiated procurement, emergency procurement and consignment to ensure that the government achieves the best value for money in sourcing essential medicines. 1 Douglas B, Tisocki K (2009) Public Procurement Prices of Medicines in the Philippines. Health Action International. 2 | P a g e What are the sources of the Price Data? The DPRI is computed based on the prevailing public tender prices of the previous year reflected in the actual Purchase Orders (POs) submitted by the DOH Retained Hospitals, RHOs, Central Office Bids and Awards Committee (COBAC) and Philippine International Trading Corporation (PITC) Pharma Inc. (PPI) to the DOH. Only data coming from reputable suppliers are considered in the database which means that they should be licensed by the Philippine Food and Drug Administration (FDA) and have a certificate of Good Manufacturing Practice issued by the FDA. How is the Drug Price Reference (DPR) determined? The DPR is set at the Median or the 50th percentile across the range of prevailing tender prices of essential medicines. For medicines with less than three (3) suppliers, the DPR may be set at the lowest winning bid price from a reputable supplier. Projected inflationary costs have already been considered in the calculation of the DPR. For innovator drugs approved for inclusion in the Philippine National Formulary, the price may be set by referencing with relevant international markets particularly those with similar income status (i.e. Thailand, India). It may also be informed by economic evaluations conducted in the Philippines used by the DOH to value their claimed clinical benefits and negotiate tender prices where an innovative pharmaceutical p ro- duct has only one sole supplier. How often shall the DPRI be updated? The DPRI shall be updated annually. All DOH hospitals and RHOs are directed to submit a copy of their POs of the previous year to the NCPAM at or before the end of the first quarter of the succeeding year. The updated DPRI shall be based on the procurement price data of medicines from the previous year. 3 | P a g e Generic Name Dosage Strength/Form Lowest-Highest DPR Tender Price (Php) (Php) A 1 Acarbose 100 mg Tablet 13.11 - 17.54 13.11 2 Acarbose 50 mg Tablet 8.23 - 11.01 8.23 3 Acetazolamide 250 mg Tablet 19.00 - 33.00 19.00 4 Acetylcysteine 100 mg Sachet 7.90 - 16.80 11.75 5 Acetylcysteine 200 mg Sachet 6.49 - 15.56 11.05 6 Acetylcysteine 200mg/mL, 25mL Bottle 1,610.84 – 1,610.84 1,650.00 7 Acetylcysteine 100mg/5mL. 150mL Suspension 290.00 - 313.00 290.00 8 Acetylcysteine 600 mg Effervescent Tablet 19.80 - 53.00 32.94 9 Aciclovir 200 mg Tablet 2.45 - 22.83 4.74 10 Aciclovir 400 mg Tablet 5.25 - 139.24 22.85 11 Aciclovir 800mg Tablet 55.00 - 206.87 70.00 12 Aciclovir 25 mg/mL, 10 mL Vial 729.94 - 938.49 729.94 13 Albendazole 400 mg Chewable Tablet 0.84 0.84 14 Albumin, Human 20% 50mL Bottle 1650.00 - 2500.00 1,650.00 15 Albumin, Human 25% 50mL Bottle 1,938.00 – 2,450.00 2,800.00 16 Alfuzosin 10mg Tablet 27.50 - 59.49 28.75 17 Allopurinol 100 mg Tablet 0.45 - 4.95 0.70 18 Allopurinol 300 mg Tablet 0.61 - 7.90 1.70 19 Alprazolam 250 mcg Tablet 4.00 - 12.72 4.00 20 Alprazolam 500 mcg Tablet 5.00 - 18.33 5.00 21 Aluminum Hydroxide + 225 mg + 200 mg/5 mL, 120 mL 17.65 - 150.00 25.00 Magnesium Hydroxide Suspension 22 Aluminum Hydroxide + 225 mg + 200 mg/5 mL, 60 mL 11.95 - 35.00 18.90 Magnesium Hydroxide Suspension 23 Amikacin (as Sulfate) 100 mg Vial 28.12 - 49.81 28.12 24 Amikacin (as Sulfate) 100 mg/mL, 2mL vial 22.08 - 22.10 22.08 25 Amikacin (as Sulfate) 125mg/mL, 2mL Vial 18.10 - 94.50 25.90 26 Amikacin (as Sulfate) 250 mg Vial 19.05 - 42.10 19.05 27 Amikacin (as Sulfate) 250 mg/mL, 2 mL Vial 16.78 - 339.00 22.40 28 Amikacin (as Sulfate) 50mg/ml, 2ml Vial 17.45 - 194.00 23.74 29 Amino Acid Solutions for Hepatic 8%, 500mL Bottle 444.44 - 480.00 444.44 Failure 30 Amino Acids, Crystalline 10%, 500mL Bottle 450.00 - 770.00 450.00 Standard 31 Amino Acids, Crystalline 5%, 500mL Bottle 400.00 - 425.00 400.00 Standard 32 Amino Acids, Crystalline 6%, 100mL Bottle 362.00 - 480.00 362.00 Standard 33 Amino Acids, Crystalline 7%, 500mL Bottle 450.00 - 500.00 450.00 Standard 34 Amino Acids, Crystalline 8%, 500mL Bottle 412.00 - 1018.00 442.22 Standard 35 Aminophylline 25 mg/mL, 10 mL Ampule 14.35 - 55.00 24.13 4 | P a g e Generic Name Dosage Strength/Form Lowest-Highest DPR Tender Price (Php) (Php) 36 Amiodarone 50 mg/mL, 3 mL Ampule 137.77 - 450.00 210.14 37 Amiodarone 200 mg Tablet 6.50 - 80.45 21.45 38 Amlodipine 10mg Tablet 0.27 - 23.26 1.05 39 Amlodipine 5 mg Tablet 0.31 - 13.24 0.94 40 Amoxicillin 100mg/mL, 10mL Drops 11.98 - 48.50 16.20 41 Amoxicillin 100mg/mL, 15mL Drops 11.44 - 33.48 18.95 42 Amoxicillin 125mg/5mL, 60mL Suspension 11.90 - 43.00 14.75 43 Amoxicillin 250 mg/5 mL, 60 mL Suspension 13.65 - 70.00 18.50 44 Amoxicillin 250 mg Capsule 0.69 - 3.81 0.95 45 Amoxicillin 500 mg Capsule 1.08 - 6.90 1.22 46 Amphotericin B (Non-Lipid 50 mg Vial 3,150.00 – 3,150.00 Complex) 5,800.00 47 Ampicillin 1g Vial 6.87 - 169.00 9.00 48 Ampicillin 250 mg Vial 4.10 - 54.25 5.98 49 Ampicillin 500 mg Vial 2.94 - 106.00 5.75 50 Ampicillin + Sulbactam 1.5g Vial 45.00 - 583.56 285.00 51 Ampicillin + Sulbactam 250mg + 125mg Vial 78.00 - 153.09 94.25 52 Ampicillin + Sulbactam 500mg + 250 mg Vial 18.42 - 702.00 87.00 53 Anti-rabies Serum (equine) 200 IU/mL,5mL Vial 940.00 - 1300.00 1,050.00 54 Anti-tetanus Serum (ATS) 1500IU/mL, 1mL Ampule 15.80 - 160.00 27.41 (equine) 55 Ascorbic Acid (Vitamin C) 100 mg/ml, 15 mL Oral Drops 9.35 - 60.90 14.98 56 Ascorbic Acid (Vitamin C) 100 mg/ml, 60 mL Oral Drops 10.07 - 13.00 11.00 57 Ascorbic
Load more

Recommended publications
  • Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K
    HANDBOOK OF Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K. Niazi CRC PRESS Boca Raton London New York Washington, D.C. Table of Contents PART I Regulatory and Manufacturing Guidance 1 Chapter 1 Current Good Manufacturing Practice Considerations in Liquid Manufacturing 3 I. Introduction 3 II. Facilities 3 III. Equipment 3 IV. Raw Materials 4 V. Compounding 4 VI. Microbiological Quality 4 VII. Oral Suspensions 5 VIII. Product Specifications 5 IX. Process Validation 5 X. Stability 5 XI. Packaging 6 Chapter 2 Stability Testing of New Drug Substances and Products 7 I. Introduction 7 II. Drug Substance 7 A. General Case 8 B. Drug Substances Intended for Storage in a Refrigerator 8 C. Drag Substances Intended for Storage in a Freezer 8 D. Drug Substances Intended for Storage below -20°C 9 HI. Drag Product 10 A. General Case •' B. Drag Products Packaged in Impermeable Containers 11 C. Drag Products Packaged in Semipermeable Containers 11 D. Drag Products Intended for Storage in a Refrigerator 12 E. Drag Products Intended for Storage in a Freezer 13 F. Drag Products Intended for Storage below -20"C 13 IV Glossary 14 References 1() Chapter 3 Container Closure Systems '7 I. Introduction '7 A. Definitions '7 B. Current Good Manufacturing Practice, the Consumer Product Safety Commission, and Requirements on Containers and Closures 17 C. Additional Considerations 17 II. Qualification and Quality Control of Packaging Components 18 A. Description 21 B. Information about Suitability 21 C. Stability Data (Packaging Concerns) 22 D. Inhalation Drag Products 23 E. Injection and Ophthalmic Drag Products 23 F.
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Department of Health
    DEPARTMENT OF HEALTH National Drug Policy - Pharmaceutical Management Unit 50 National Formulary Committee Philippine National Drug Formulary EssentialEssential MedicinesMedicines ListList Volume I, 7th Edition ( 2008 ) Published by: The National Formulary Committee National Drug Policy ‐ Pharmaceutical Management Unit 50 DEPARTMENT OF HEALTH Manila, Philippines All rights reserved 2008 The National Formulary Committee National Drug Policy‐Pharmaceutical Management Unit 50 (NDP‐PMU 50) Department of Health San Lazaro Cmpd., Rizal Ave., Sta. Cruz, Manila, Philippines 1003 ISBN 978‐971‐91620‐7‐0 Any part or the whole book may be reproduced or transmitted without any alteration, in any form or by any means, with permission from DOH provided it is not sold commercially. ii PHILIPPINE NATIONAL DRUG FORMULARY Volume I, 7th Edition 2 0 0 8 Francisco T. Duque III, MD, MSc Secretary of Health Alexander A. Padilla Undersecretary of Health, Office for External Affairs Robert Louie P. So, MD Program Manager, NDP-PMU 50 Dennis S. Quiambao, MD Proj. Mgmt. Operating Officer & Coordinator (PMOOC) NDP-PMU 50 NATIONAL FORMULARY COMMITTEE Estrella B. Paje-Villar, MD, DTM & H Chairperson Jose M. Acuin, MD, MSc Alma L. Jimenez, MD Alejandro C. Baroque II, MD Marieta B. de Luna, MD Bu C. Castro, MD Nelia P. Cortes-Maramba, MD Dina V. Diaz, MD Yolanda R. Robles, PhD Pharm Mario R. Festin, MD, MS, MHPEd Isidro C. Sia, MD BFAD Representative SECRETARIAT Luzviminda O. Marquez, RPh, RMT Mary Love C. Victoria, RPh Michael D. Junsay, RPh Ermalyn M. Magturo iii Republic of the Philippines DEPARTMENT OF HEALTH OFFICE OF THE SECRETARY 2/F Bldg. 1, San Lazaro Cmpd., Rizal Avenue, Sta.
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors
    저작자표시-비영리-변경금지 2.0 대한민국 이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게 l 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다. 다음과 같은 조건을 따라야 합니다: 저작자표시. 귀하는 원저작자를 표시하여야 합니다. 비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다. 변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다. l 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건 을 명확하게 나타내어야 합니다. l 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다. 저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다. 이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다. Disclaimer 약학 석사학위 논문 안지오텐신 전환 효소 억제제 개시 이후 진해제의 사용 분석 Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors 2017년 8월 서울대학교 대학원 약학과 사회약학전공 권 익 태 안지오텐신 전환 효소 억제제 개시 이후 진해제의 사용 분석 Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors 지도교수 홍 송 희 이 논문을 권익태 석사학위논문으로 제출함 2017년 4월 서울대학교 대학원 약학과 사회약학전공 권 익 태 권익태의 석사학위논문을 인준함 2017년 6월 위 원 장 (인) 부 위 원 장 (인) 위 원 (인) Abstract Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors Ik Tae Kwon Department of Social Pharmacy College of Pharmacy, Seoul National University Background Angiotensin-converting enzyme inhibitors (ACEI) can induce a dry cough, more frequently among Asians. If healthcare professionals fail to detect coughs induced by an ACEI, patients are at risk of getting antitussives inappropriately instead of discontinuing ACEI. The purpose of this study was to examine how the initiation of ACEI affects the likelihood of antitussive uses compared with the initiation of Angiotensin Receptor Blocker (ARB) and to determine the effect of the antitussive use on the duration and adherence of therapy in a Korean population.
    [Show full text]
  • L:\0901 with Peru\0901PHARMAPPX.Wpd
    Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACODAZOLE 79152-85-5 ABLUKAST 96566-25-5 ACOLBIFENE 182167-02-8 ABRINEURIN 178535-93-8 ACONIAZIDE 13410-86-1 ABUNIDAZOLE 91017-58-2 ACOTIAMIDE 185106-16-5 ACADESINE 2627-69-2 ACOXATRINE 748-44-7 ACAMPROSATE 77337-76-9 ACREOZAST 123548-56-1 ACAPRAZINE 55485-20-6
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • National OTC Medicines List-2018
    National OTC Medicines List – First Edition 2018 NATIONAL OTC MEDICINES LIST First Edition 2018 Foreword According to the French National Agency for Medicines and Health Products Safety (ANSM), Over‐the‐ counter (OTC) drugs are medicines that are accessible to patients in pharmacies, based on criteria set to safeguard patients’ safety. FDA’s Center for Drug Evaluation and Research (CDER) regulates over‐the‐counter (OTC) which are drugs that have been found to be safe and appropriate for use without the supervision of a health care professional such as a physician, and they can be purchased by consumers without a prescription. Due to their therapeutic class, these medicines could be dispensed without physician’s intervention for diagnostic, treatment initiation or maintenance purposes. According to Arcle 43 of the Law No.367 issued in 1994 related to the pharmacy practice, and the amendment of Arcles 46 and 47 by Law No.91 issued in 2010, pharmacists do not have the right to dispense any medicine that is not requested through a unified prescription, unless the medicine is mentioned in a list which is established by the Orders of Pharmacists and Physicians In this regards, the Ministry of Public Health (MoPH) developed the National OTC list, presented it in a scientific, objective, reliable and accessible listingand issued by a Ministerial decision. At this stage, no “convenience size packaging” nor “restriction to a maximum dose” or a “maximum dose per day” or “length of treatment” were considered for some molecules to allow them to be classified as OTC. The list covers medicines that are intended to relief patients from minor to moderate symptoms for a determined period, and procured with the pharmacist’s assistance without the physician’s intervention.
    [Show full text]
  • < MOH Approved Drugs List >
    Ministry Of Health Directorate General of Medical Supplies Rep_Id : App_Drugs_List_Who.rdf < MOH Approved Drugs List > DATE : 12/08/2009 Page : 1 of 108 VED Flag <S.No> < Item Code > < I T E M D E S C ROF I P- T I O N > < U N I T > DATE : ABC Flag H/C Flag Category : DRUGS 1 Ph. System : GASTRO-INTESTINAL SYSTEM 1 Main Group : ANTACIDS 1 Sub Group : ALUMINIUM COMPOUNDS 1 03000000105 ALUMINIUM HYDROXIDE GEL, DRIED 475 MG. CAPSULE Desirable Cat_C Not H/C Item 2 Sub Group : ANTACID COMPOUND PREPARATIONS 2 02000000079 ANTACID SUSPENSION (ALUMINIUM HYDROXIDE + BOTTLE Desirable MAGNESIUM HYDROXIDE OR TRISILICATE) 100 - 200 Cat_A ML. B0TTLE. H/C Item 3 03000000173 ANTACID TABLET (ALUMINIUM HYDROXIDE + TABLET/CAP Desirable MAGNESIUM HYDROXIDE OR TRISILICATE). Cat_A H/C Item 2 Main Group : ANTISPASMODICS 1 Sub Group : ANTIMUSCARINICS 4 01000000304 HYOSCINE N BUTYLBROMIDE 20MG/ML. 1ML. AMPOULE Essantial Cat_A H/C Item 5 03000000640 HYOSCINE N BUTYL BROMIDE 10MG. TABLET/CAP Essantial Cat_A H/C Item 6 020D0000063 ANTISPASMODIC DROPS 15ML-25ML. BOTTLE Desirable Cat_C Not H/C Item 2 Sub Group : OTHER ANTISPASMODIC AND MOTILITY STIMULANT 7 03000001245 MEBEVERINE HYDROCHLORIDE 100 MG - 135 MG. TABLET/CAP Essantial Cat_B Not H/C Item Ministry Of Health Directorate General of Medical Supplies Rep_Id : App_Drugs_List_Who.rdf < MOH Approved Drugs List > DATE : 12/08/2009 Page : 2 of 108 VED Flag <S.No> < Item Code > < I T E M D E S C ROF I P- T I O N > < U N I T > DATE : ABC Flag H/C Flag Category : DRUGS 1 Ph.
    [Show full text]
  • Non-Prescription Analgesic and Antitussive Medications Containing Codeine: a Review of Clinical Effectiveness and Safety
    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Non-prescription Analgesic and Antitussive Medications Containing Codeine: A Review of Clinical Effectiveness and Safety Service Line: Rapid Response Service Version: 1.0 Publication Date: June 20, 2018 Report Length: 48 Pages Authors: Yi-Sheng Chao, Melissa Severn Cite As: Non-prescription Analgesic and Antitussive Medications Containing Codeine: A Review of Clinical Effectiveness and Safety. Ottawa: CADTH; 2018 Jun. (CADTH Rapid response report: summary with critical appraisal). Acknowledgments: ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect.
    [Show full text]
  • Class Update: Cough & Cold Preparations
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Class Update: Cough & Cold Preparations Date of Review: May 2016 Date of Last Review: May 2013; Codeine DUE July 2015 Current Status of Preferred Drug List (PDL) Class: See Appendix 1. Purpose for Class Update: Four reviews1,2, 3,4 that help to clarify the available evidence for cough treatments, new United States Food and Drug Administration (FDA) safety warnings on codeine in children,5,6 and new treatment guidelines7 were published since the last class update. Research Questions: 1. What is the comparative evidence for available cough and cold treatments (including over‐the‐counter [OTC]) to reduce the severity or frequency of cough and cold? 2. What is the comparative evidence for available cough and cold treatments for safety? 3. Are there specific populations (e.g. children) where cough and cold treatments are safer or more effective? Conclusions: The evidence is limited by few direct comparisons of the multiple combination products available, heterogeneous cough etiologies and small study sizes. There is insufficient evidence for efficacy of expectorants for cough1 and expectorants are not recommended for cough secondary to any cause.8 There is low quality evidence that various opioids (primarily codeine) and dextromethorphan reduce cough severity and cough frequency compared to placebo in patients with unexplained or refractory cough symptoms.1 Comparisons of opioids to dextromethorphan had mixed results.1 There was insufficient evidence of efficacy for benzonatate or antihistamines.1 There is low quality evidence that various combinations of antihistamines and decongestants have limited effect on “global effectiveness” for the common cold in adults and older children.9 There is no evidence of benefit in young children.9 There is insufficient comparative safety evidence.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]